Fortitude Biomedicines enters the degradation race with catalytic ADC platform GLUE-DACTM
Fortitude Biomedicines launches with $13M to develop glue-payload ADCs for autoimmune and cancer treatment. Find out what makes this platform different.
Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Will IFx-2.0 and TBS-2025 push TuHURA into the frontline of resistance-focused oncology?
TuHURA Biosciences, Inc. has announced a comprehensive corporate update that includes progress across three of its major immuno-oncology programs. The update covers the company’s lead asset IFx-2.0, currently in a Phase 3 trial in combination with pembrolizumab for advanced Merkel cell carcinoma; the next-stage development of TBS-2025, a VISTA-blocking monoclonal antibody being advanced for relapsed […]